Clone:
REAL283
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC
Alternative names:
KLRC1, CD159a, NKG2, NKG2A

Extended validation for CD159a (NKG2A) Antibody, anti-human,
REAlease
®

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REAL283
REA110++
131411+
Z199++
Cells were incubated with an excess of purified unconjugated CD159a (NKG2A) (REAL283) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for CD159a (NKG2A) Antibody, anti-human,
REAlease
®

Overview

Clone REAL283 is an antibody fragment derived from the full CD159a (NKG2A) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL283 recognizes CD159a, an inhibitory natural killer (NK) cell receptor. CD159a forms heterodimer with CD94 and contains a C-type lectin ectodomain. Inhibitory signal is transmitted by the heterodimer via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and upon ligand engagement, ITIMs are phosphorylated and transmit signal through docking of various tyrosine phosphatases. CD159a/CD94 binds non-classical MHC class I protein, HLA-E. Expression of CD159a is found mainly on NK cells and on subsets of CD8
+
cells.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

KLRC1, CD159a, NKG2, NKG2A

Detailed product information

Technical specifications

CloneREAL283
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD159a (NKG2A)
Alternative names of antigenKLRC1, CD159a, NKG2, NKG2A
Distribution of antigenNK cells, T cells, CD8+ T cells
RRIDAB_2751296, AB_2751623, AB_2751579, AB_2751308, AB_2751299, AB_2783971, AB_2783972, AB_2783970, AB_2751305

References for CD159a (NKG2A) Antibody, anti-human,
REAlease
®

Publications

  1. Boyington, J. C. et al. (1999) Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity 10(1): 75-82
  2. Sullivan, L. C. et al. (2007) The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 27(6): 900-911
  3. Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10(10): e0139603
  4. Veluchamy, J. P. et al. (2017) High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol. Immunother. 66: 51-61
  5. Jacomet, F. et al. (2017)
    The hypothesis of the human iNKT/innate CD8
    +
    T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia.
    Front Immunol 7: 688

Related products for
CD159a (NKG2A) Antibody, anti-human,
REAlease
®

3 products available